Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13930752 | 1.00 | RAB9A (0.41) | RAB9APOLBTHRBMAPTALDH1A1 | |
| SCHEMBL13930754 | 0.89 | THRB (0.38) | RAB9APOLBTHRBMAPTALDH1A1 | |
| SCHEMBL13930735 | 0.88 | OPRM1 (0.47) | RAB9APOLBTHRBMAPTTP53 | |
| SCHEMBL13930847 | 0.88 | OPRM1 (0.47) | RAB9APOLBTHRBMAPTTP53 | |
| SCHEMBL13952151 | 0.79 | FUCA1 (0.45) | RAB9APOLBALDH1A1TP53CHRM2 | |
| SCHEMBL13931017 | 0.79 | FUCA1 (0.45) | RAB9APOLBALDH1A1TP53CHRM2 | |
| SCHEMBL13931016 | 0.74 | RAB9A (0.44) | RAB9APOLBMAPTTP53 | |
| SCHEMBL13930709 | 0.72 | MAPT (0.42) | RAB9AMAPTALDH1A1RORCTP53 | |
| SCHEMBL13930728 | 0.72 | MAPT (0.59) | POLBMAPTALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL13929310 | 0.72 | SIGMAR1 (0.58) | RORCOPRM1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | EUROSCREEN S.A. (BE) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048291-A1 | Novel Piperidine-4-Acetic Acid Derivatives and Their Use | ALDH1A1, ABAT, ALDH18A1 | RAB9A 729/4885POLB 1789/4885THRB 3487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.